Skip to main content
SpringerLink
Log in

Langzeitdaten für VMP beim multiplen Myelom

  • Literatur kompakt
  • Leukämien und Lymphome
  • Published:
Im Focus Onkologie Aims and scope

Die Zugabe von Bortezomib (V) zum Standardregime aus Melphalan und Prednison (MP) in der Therapie multipler Myelome verlängert das Überleben. Aber ist der Effekt auch nach fünf Jahren noch erkennbar?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  • San Miguel JF et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31(4):448–55.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Christina Berndt

Authors
  1. Christina Berndt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berndt, C. Langzeitdaten für VMP beim multiplen Myelom. Im Focus Onkologie 16, 26 (2013). https://doi.org/10.1007/s15015-013-0644-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-013-0644-2

Search

Navigation